Get 40% Off
💰 Ray Dalio just increased his holdings in Google by 162.61% - See the full portfolio with InvestingPro’s free Stock Ideas toolCopy Portfolios

Catalyst Bio launches Phase 2/3 study of hemophilia candidate marzeptacog alfa

Published 01/04/2018, 11:38 AM
© Reuters.  Catalyst Bio launches Phase 2/3 study of hemophilia candidate marzeptacog alfa
GYRE
-
  • Catalyst Biosciences (CBIO -5%) commences enrollment in the Phase 2 portion of a Phase 2/3 clinical trial evaluating subcutaneously administered marzeptacog alfa (activated) (MarzAA) for prophylaxis in hemophilia A or B patients without inhibitors.
  • The open-label 12-subject study will assess the ability of MarzAA to minimize or eliminate spontaneous bleeds. The primary endpoint is the reduction in annualized bleed rate compared to each participant's historical rate.
  • Preliminary data should be available in H1.
  • MarzAA is a Factor VIIa therapy that has Orphan Drug status in the U.S. for routine prophylaxis in hemophilia A or B.
  • Shares are down on profit-taking after a three-fold runup since mid-November.
  • Now read: Insmed (INSM) ALIS Clinical Update - Slideshow


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.